Consistent lowering of clotting factors for the treatment of acute cardiovascular syndromes and hypercoagulability: A different pathophysiological approach

被引：24

作者：

Jaeger, BR

Goehring, P

Schirmer, J

Uhrig, S

Lohse, P

Kreuzer, E

Reichart, B

Seidel, D

机构：

[1] Univ Munich, Univ Hosp Grosshadern, Inst Clin Chem, D-81377 Munich, Germany

[2] Univ Munich, Univ Hosp Grosshadern, Dept Cardiac Surg, D-81377 Munich, Germany

来源：

THERAPEUTIC APHERESIS | 2001年 / 5卷 / 04期

关键词：

atherosclerosis; cardiovascular diseases; cholesterol; coagulation; fibrinogen; low-density lipoprotein apheresis; thrombolysis;

D O I：

10.1046/j.1526-0968.2001.00350.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hypercoagulability is a key contributor to acute cardiovascular syndromes and to various microcirculatory disorders. The use of heparin-mediated extracorporeal low-density lipoprotein/fibrinogen precipitation (HELP) apheresis makes a controlled, immediately effective reduction of clotting factors possible, and induces subsequent positive effects on plasma viscosity, erythrocyte aggregation, and microcirculation. Oxygen supply to an ischemic artery can thus be increased without hemodilution, qualifying the HELP system as a possible therapeutic tool in the treatment of acute cardiovascular syndromes and microcirculatory disorders.

引用

页码：252 / 259

页数：8

共 38 条

[1] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].

ALTMAN, R ;

CARRERAS, L ;

DIAZ, R ;

FIGUEROA, E ;

PAOLASSO, E ;

PARODI, JC ;

CADE, JF ;

DONNAN, G ;

EADIE, MJ ;

GAVAGHAN, TP ;

OSULLIVAN, EF ;

PARKIN, D ;

RENNY, JTG ;

SILAGY, C ;

VINAZZER, H ;

ZEKERT, F ;

ADRIAENSEN, H ;

BERTRANDHARDY, JM ;

BRAN, M ;

DAVID, JL ;

DRICOT, J ;

LAVENNEPARDONGE, E ;

LIMET, R ;

LOWENTHAL, A ;

MORIAU, M ;

SCHAPIRA, S ;

SMETS, P ;

SYMOENS, J ;

VERHAEGHE, R ;

VERSTRAETE, M ;

ATALLAH, A ;

BARNETT, H ;

BATISTA, R ;

BLAKELY, J ;

CAIRNS, JA ;

COTE, R ;

CROUCH, J ;

EVANS, G ;

FINDLAY, JM ;

GENT, M ;

LANGLOIS, Y ;

LECLERC, J ;

NORRIS, J ;

PINEO, GF ;

POWERS, PJ ;

ROBERTS, R ;

SCHWARTZ, L ;

SICURELLA, J ;

TAYLOR, W ;

THEROUX, P .

BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100

[2]

CLAUSS A., 1957, ACTA HAEMATOL, V17, P237

[3]

COLMAN RW, 1994, HEMOSTASIS THROMBOSI, P3

[4] Ten-year follow-up results from the Goettingen risk, incidence and prevalence study (GRIPS) .1. Risk factors for myocardial infarction in a cohort of 5790 men [J].

Cremer, P ;

Nagel, D ;

Mann, H ;

Labrot, B ;

MullerBerninger, R ;

Elster, H ;

Seidel, D .

ATHEROSCLEROSIS, 1997, 129 (02) :221-230

[5] PLASMA-FIBRINOGEN - AN INDEPENDENT CARDIOVASCULAR RISK FACTOR [J].

ERNST, E .

JOURNAL OF INTERNAL MEDICINE, 1990, 227 (06) :365-372

[6] INTERNAL DUPLICATION AND SEQUENCE HOMOLOGY IN FACTOR-V AND FACTOR-VIII [J].

FASS, DN ;

HEWICK, RM ;

KNUTSON, GJ ;

NESHEIM, ME ;

MANN, KG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (06) :1688-1691

[7] MECHANISMS LEADING TO MYOCARDIAL-INFARCTION - INSIGHTS FROM STUDIES OF VASCULAR BIOLOGY [J].

FUSTER, V .

CIRCULATION, 1994, 90 (04) :2126-2146

[8] FIBRINOGEN AND FACTOR-VII IN THE PREDICTION OF CORONARY RISK - RESULTS FROM THE PROCAM STUDY IN HEALTHY-MEN [J].

HEINRICH, J ;

BALLEISEN, L ;

SCHULTE, H ;

ASSMANN, G ;

VANDELOO, J .

ARTERIOSCLEROSIS AND THROMBOSIS, 1994, 14 (01) :54-59

[9]

HUNT BJ, 1991, TRANSPLANT P, V23, P1233

[10] PLASMA-FIBRINOGEN AND ITS CORRELATES IN JAPANESE AND UNITED-STATES POPULATION SAMPLES [J].

ISO, H ;

FOLSOM, AR ;

SATO, S ;

WU, KK ;

SHIMAMOTO, T ;

KOIKE, K ;

IIDA, M ;

KOMACHI, Y .

ARTERIOSCLEROSIS AND THROMBOSIS, 1993, 13 (06) :783-790

← 1 2 3 4 →